It was well written. And seeing both Leo and Dr.
Post# of 72440
They could break some better news next week.
Getting this taken care of soon would be a good thing.
Prurisol for Psoriasis
· A top priority of the Company remains to unblind and analyze topline results from its completed Phase 2b trial (see NCT02949388) of oral Prurisol for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis. Enrolling up to 199 patients, and based upon the protocol for 12 weeks of Prurisol treatment and an additional patient follow-up for 4 weeks, the study builds on a prior successfully completed Phase 2 trial of oral Prurisol in Mild-to-Moderate Chronic Plaque Psoriasis. A novel Psoriasis drug, particularly one that is oral, safe and effective, which could expand patient and physician choices for treatment, likely would command significant market value.